NICE rejects omalizumab for asthma in children

Using omalizumab (Xolair) to treat children with persistent allergic asthma does not represent good value for NHS money, NICE has said.

In its latest draft guidance, NICE said it is unable to recommend omalizumab for severe persistent allergic asthma in children aged six to 11 years.

Dr Gillian Leng, NICE’s deputy chief executive, said that available evidence demonstrated ‘no proven reduction in hospitalisation rates, accident and emergency visits, unscheduled doctor visits or total emergency visits for children in this age group treated with omalizumab’.

‘The [Independent Appraisal Committee] found that omalizumab is only useful in reducing the rate of clinically significant exacerbations for children who had had three or more exacerbations per year,’ she said.

‘We are unable to recommend that NHS funds be diverted to a treatment with such high costs which only provides very limited benefits for patients.’

Xolair’s manufacturer Novartis Pharmaceuticals said it was disappointed with NICE’s draft decision.

'Omalizumab is the first in a new generation of drugs for severe, difficult-to-control allergic asthma, where patients have an oversensitive immune system, and is already recommended by NICE for use in a high risk subgroup of patients aged 12 years and older,' a spokesman said.

Final guidance is due to be issued next month. In the meantime, children currently receiving omalizumab should have the opportunity to continue treatment until it is considered appropriate to stop.

Dr Mike Thomas, chief medical adviser to Asthma UK, said: 'Hundreds of children across England with the most severe, allergic asthma, will now be denied a pioneering treatment that could free them from crippling daily asthma symptoms, endless trips to hospital and huge amounts of time off school.

'As the Scottish Medicines Consortium has already approved omalizumab (Xolair) for use in children aged six to 11 in Scotland, patients will once again be faced with a treatment postcode lottery depending on where they live in the UK.

'For parents of children with severe asthma aged six to 11 who have already trialled Xolair and had their lives transformed, this news will come as a massive blow. It's vital that these children do not have the treatment withdrawn by PCTs as a result of the NICE decision, as this would be completely unjust.

'We will continue to fight for Xolair to be made available to people of all ages with severe asthma throughout the UK.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

No plans to impose face-to-face GP appointment targets, Hancock tells BMA

The government has no plans to impose face-to-face appointments targets on general...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

COVID-19 variants could force UK to revaccinate over next 2-3 years warns CMO

The UK's chief medical adviser has warned that new coronavirus variants may force...

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

BMA condemns 'fundamentally flawed' £20m weight management enhanced service

The BMA has condemned a £20m weight management enhanced service as 'fundamentally...

GP contract update delivers extra PCN cash and £50m for new enhanced services

GP contract update delivers extra PCN cash and £50m for new enhanced services

An update to the GP contract agreement for 2021/22 has set out details of enhanced...

CQC rejects call for independent review to look at BAME bias in ratings

CQC rejects call for independent review to look at BAME bias in ratings

The CQC has rejected calls for an independent review of its ratings process to look...